Showing results (31-40 of 301) with videos related to
Sort By:
Pageof 31
Biomedicines|March 29, 2018
NF-κB Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted TherapyPaula Grondona, Philip Bucher, Klaus Schulze-Osthoff, et al.Blood|December 4, 2019
Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphomaPhilip Bucher, Tabea Erdmann, Paula Grondona, et al.International Journal of Cancer|January 6, 2007
Regulation of P53 stability in p53 mutated human and mouse hepatoma cellsStephan Hailfinger, Maike Jaworski, Philip Marx-Stoelting, et al.British Journal of Haematology|April 1, 2022
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trialGeorg Hess, Andreas Hüttmann, Mathias Witzens-Harig, et al.Blood Advances|November 7, 2023
Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stressBeatriz Gomez Solsona, Heike Horn, Anja Schmitt, et al.Cancer Treatment Reviews|March 18, 2018
Targeting the B-cell receptor pathway in diffuse large B-cell lymphomaKieron Dunleavy, Tabea Erdmann, Georg LenzTherapeutic Advances in Hematology|April 5, 2013
The molecular biology of diffuse large B-cell lymphomaMareike Frick, Bernd Dörken, Georg LenzDeutsche Medizinische Wochenschrift (1946)|February 5, 2020
[Current diagnostic and therapeutic standards in aggressive B-cell lymphomas]Birte Friedrichs, Norbert Schmitz, Georg LenzCancer|August 27, 2004
The role of fludarabine in the treatment of follicular and mantle cell lymphomaGeorg Lenz, Wolfgang Hiddemann, Martin DreylingBest Practice & Research. Clinical Haematology|March 14, 2012
New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphomaMareike Frick, Bernd Dörken, Georg LenzPageof 31